Limits...
Elevated peripheral visfatin levels in narcoleptic patients.

Dahmen N, Manderscheid N, Helfrich J, Musholt PB, Forst T, Pfützner A, Engel A - PLoS ONE (2008)

Bottom Line: It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF).Peripheral visfatin levels were measured using a commercial enzyme immunoassay kit with a measurement range from 0.1-1000 ng/ml.Circulating visfatin was found to be significantly increased in HLA DR2 positive narcoleptic patients compared to controls.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, University of Mainz, Mainz, Germany.

ABSTRACT

Objective: Narcolepsy is a severe sleep disorder that is characterized by excessive daytime sleepiness, cataplexies and a tendency towards obesity. Recent discoveries indicate that the major pathophysiology is a loss of hypocretin (orexin) producing neurons due to immunologically mediated degeneration. Visfatin is a recently described proinflammatory adipokine. It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF). Our study examines the hypothesis that visfatin levels are altered in narcoleptic patients.

Methods: For the analysis, a total of n = 54 patients (n = 18 males and n = 36 females) with the diagnosis of narcolepsy according to DSM-IV and the International Classification of Sleep Disorders were examined (BMI mean 30.3+/-5.5, age mean 52.5+/-16.1 years). As a control group 39 unrelated (n = 12 males and n = 27 females) healthy volunteers with no sleep disorder according to DSM-IV were included (BMI mean 28.5+/-4.6, age mean 51.1+/-13.6 years). Peripheral visfatin levels were measured using a commercial enzyme immunoassay kit with a measurement range from 0.1-1000 ng/ml. Narcolepsy symptoms, severity and frequency of symptoms as well as the total duration of various aspects of the symptomatology were assessed by unstructured and structured clinical interviews in including the Stanford Center for Narcolepsy Sleep Inventory.

Results: Circulating visfatin was found to be significantly increased in HLA DR2 positive narcoleptic patients compared to controls.

Conclusion: Taken together, our results add to the evidence of disturbed immunological regulation in patients with narcolepsy.

Show MeSH

Related in: MedlinePlus

Boxplot comparing controls with narcoleptics, outliers above 100 ng/ml (one individual of the control group, five narcoleptic patients) are not depicted.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2500162&req=5

pone-0002980-g001: Boxplot comparing controls with narcoleptics, outliers above 100 ng/ml (one individual of the control group, five narcoleptic patients) are not depicted.

Mentions: Closer examination of the data revealed that the group difference between narcoleptics and controls was mainly driven by the HLA DR2 positive narcoleptics (BMI 31.1±5.1; p = 0.51 compared to controls; age 54.2±16.2; p = 0.23 compared to controls). The median of the HLA DR2 positive narcoleptics was 36.2 ng/ml (interquartile range 21.0–57.5) vs. 20.2 ng/ml in HLA-neg. narcoleptics (interquartile range 12.6–35.2; p = 0.036) vs. 19.4 ng/ml in the controls (interquartile range 15.3–31.5; p = 0.010; figure 1). No differences between HLA positive and negative controls were apparent. The median of the HLA DR2 positive controls was 19.4 ng/ml (interquartile range 12.7–40.8) vs. 20.4 ng/ml in HLA-neg. controls (interquartile range 16.0–36.1; p = 0.756).


Elevated peripheral visfatin levels in narcoleptic patients.

Dahmen N, Manderscheid N, Helfrich J, Musholt PB, Forst T, Pfützner A, Engel A - PLoS ONE (2008)

Boxplot comparing controls with narcoleptics, outliers above 100 ng/ml (one individual of the control group, five narcoleptic patients) are not depicted.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2500162&req=5

pone-0002980-g001: Boxplot comparing controls with narcoleptics, outliers above 100 ng/ml (one individual of the control group, five narcoleptic patients) are not depicted.
Mentions: Closer examination of the data revealed that the group difference between narcoleptics and controls was mainly driven by the HLA DR2 positive narcoleptics (BMI 31.1±5.1; p = 0.51 compared to controls; age 54.2±16.2; p = 0.23 compared to controls). The median of the HLA DR2 positive narcoleptics was 36.2 ng/ml (interquartile range 21.0–57.5) vs. 20.2 ng/ml in HLA-neg. narcoleptics (interquartile range 12.6–35.2; p = 0.036) vs. 19.4 ng/ml in the controls (interquartile range 15.3–31.5; p = 0.010; figure 1). No differences between HLA positive and negative controls were apparent. The median of the HLA DR2 positive controls was 19.4 ng/ml (interquartile range 12.7–40.8) vs. 20.4 ng/ml in HLA-neg. controls (interquartile range 16.0–36.1; p = 0.756).

Bottom Line: It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF).Peripheral visfatin levels were measured using a commercial enzyme immunoassay kit with a measurement range from 0.1-1000 ng/ml.Circulating visfatin was found to be significantly increased in HLA DR2 positive narcoleptic patients compared to controls.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, University of Mainz, Mainz, Germany.

ABSTRACT

Objective: Narcolepsy is a severe sleep disorder that is characterized by excessive daytime sleepiness, cataplexies and a tendency towards obesity. Recent discoveries indicate that the major pathophysiology is a loss of hypocretin (orexin) producing neurons due to immunologically mediated degeneration. Visfatin is a recently described proinflammatory adipokine. It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF). Our study examines the hypothesis that visfatin levels are altered in narcoleptic patients.

Methods: For the analysis, a total of n = 54 patients (n = 18 males and n = 36 females) with the diagnosis of narcolepsy according to DSM-IV and the International Classification of Sleep Disorders were examined (BMI mean 30.3+/-5.5, age mean 52.5+/-16.1 years). As a control group 39 unrelated (n = 12 males and n = 27 females) healthy volunteers with no sleep disorder according to DSM-IV were included (BMI mean 28.5+/-4.6, age mean 51.1+/-13.6 years). Peripheral visfatin levels were measured using a commercial enzyme immunoassay kit with a measurement range from 0.1-1000 ng/ml. Narcolepsy symptoms, severity and frequency of symptoms as well as the total duration of various aspects of the symptomatology were assessed by unstructured and structured clinical interviews in including the Stanford Center for Narcolepsy Sleep Inventory.

Results: Circulating visfatin was found to be significantly increased in HLA DR2 positive narcoleptic patients compared to controls.

Conclusion: Taken together, our results add to the evidence of disturbed immunological regulation in patients with narcolepsy.

Show MeSH
Related in: MedlinePlus